Elanco Animal Health (NYSE:ELAN) Updates FY25 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.80-$0.86 for the period, compared to the consensus earnings per share estimate of $0.89. The company issued revenue guidance of $4.445-$4.510 billion, compared to the consensus revenue estimate of $4.52 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Elanco Animal Health Price Performance

ELAN stock traded down $0.04 during trading on Thursday, reaching $11.10. 1,161,590 shares of the company were exchanged, compared to its average volume of 4,840,683. The company has a market capitalization of $5.48 billion, a price-to-earnings ratio of 27.61, a P/E/G ratio of 2.50 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a 50-day moving average of $11.74 and a two-hundred day moving average of $13.06. Elanco Animal Health has a twelve month low of $10.20 and a twelve month high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company posted $0.08 earnings per share. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. As a group, equities analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on ELAN. UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday. Stifel Nicolaus cut their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Leerink Partners started coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target for the company. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, Barclays reduced their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $15.57.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.